IL229376B - Controlled-release peptide formulations - Google Patents
Controlled-release peptide formulationsInfo
- Publication number
- IL229376B IL229376B IL22937613A IL22937613A IL229376B IL 229376 B IL229376 B IL 229376B IL 22937613 A IL22937613 A IL 22937613A IL 22937613 A IL22937613 A IL 22937613A IL 229376 B IL229376 B IL 229376B
- Authority
- IL
- Israel
- Prior art keywords
- controlled release
- peptide formulations
- release peptide
- formulations
- controlled
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489886P | 2011-05-25 | 2011-05-25 | |
| PCT/EP2012/059917 WO2012160213A1 (en) | 2011-05-25 | 2012-05-25 | Controlled release peptide formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL229376A0 IL229376A0 (en) | 2014-01-30 |
| IL229376B true IL229376B (en) | 2019-11-28 |
Family
ID=46456496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL22937613A IL229376B (en) | 2011-05-25 | 2013-11-11 | Controlled-release peptide formulations |
Country Status (37)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1768650T3 (pl) * | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| JP6375289B2 (ja) * | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| PE20150195A1 (es) * | 2012-05-25 | 2015-02-27 | Camarus Ab | Formulaciones de agonistas del receptor de somatostatina |
| AU2013294915C1 (en) | 2012-07-26 | 2019-11-21 | Camurus Ab | Opioid formulations |
| ES2837803T3 (es) | 2012-07-26 | 2021-07-01 | Camurus Ab | Formulaciones de opioides |
| WO2018013924A1 (en) | 2016-07-15 | 2018-01-18 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| JP7527785B2 (ja) | 2016-09-15 | 2024-08-05 | カムルス エービー | プロスタサイクリン類似体製剤 |
| MX383392B (es) | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| WO2019099735A1 (en) * | 2017-11-15 | 2019-05-23 | Rhythm Pharmaceuticals, Inc. | Sustained release peptide formulations |
| US12247052B2 (en) | 2018-03-02 | 2025-03-11 | Elicio Therapeutics, Inc. | CpG amphiphiles and uses thereof |
| CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
| JP2022525781A (ja) | 2019-03-20 | 2022-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫細胞療法における両親媒性物質の使用およびそのための組成物 |
| CA3141337A1 (en) * | 2019-05-24 | 2020-12-03 | Piedmont Animal Health Inc. | Long-acting injectable formulations and use thereof |
| MX2021014450A (es) | 2019-05-29 | 2022-01-06 | Camurus Ab | Composiciones de liberacion controlada de lipidos. |
| CN113368041B (zh) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | 药物组合物、缓释制剂及其制备方法 |
| CA3217408A1 (en) * | 2021-05-04 | 2022-11-10 | Fredrik Tiberg | Compositions and methods for treating neuroendocrine tumors |
| EP4731247A1 (en) * | 2023-06-20 | 2026-04-29 | Camurus AB | Compositions and methods for treating acromegaly |
| WO2025229402A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
| WO2025229403A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
| WO2026125238A1 (en) | 2024-12-10 | 2026-06-18 | Camurus Ab | Compositions and methods of use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1682091T3 (pl) * | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| PL1768650T3 (pl) * | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| GB0417388D0 (en) | 2004-08-04 | 2004-09-08 | Camurus Ab | Composition |
| JP5513713B2 (ja) | 2004-08-04 | 2014-06-04 | カムルス エービー | 非層状分散を生じる組成物 |
| KR100983746B1 (ko) * | 2005-01-14 | 2010-09-24 | 카무러스 에이비 | 소마토스타틴 유사 제형 |
| EP1843746B1 (en) * | 2005-01-14 | 2011-03-16 | Camurus Ab | Somatostatin analogue formulations |
| PL1845942T3 (pl) * | 2005-01-14 | 2014-07-31 | Camurus Ab | Preparaty analogu GnRH |
| AU2005325510B2 (en) * | 2005-01-21 | 2009-07-02 | Camurus Ab | Pharmaceutical lipid compositions |
| EP1909824B1 (en) * | 2005-04-08 | 2011-05-18 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| US8097239B2 (en) * | 2005-06-06 | 2012-01-17 | Camurus Ab | Controlled-release formulations |
| PL1888031T3 (pl) * | 2005-06-06 | 2013-04-30 | Camurus Ab | Preparaty analogu glp-1 |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| US8931272B2 (en) * | 2010-10-29 | 2015-01-13 | Ford Global Technologies, Llc | Method and system for limiting output of a boosted engine |
| US9555118B2 (en) * | 2011-12-05 | 2017-01-31 | Camrus Ab | Robust controlled-release peptide formulations |
| PE20150195A1 (es) * | 2012-05-25 | 2015-02-27 | Camarus Ab | Formulaciones de agonistas del receptor de somatostatina |
| US20230285502A1 (en) * | 2016-09-07 | 2023-09-14 | Camurus Ab | Mixtures and formulations |
| MX383392B (es) * | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
-
2012
- 2012-05-25 BR BR112013030104A patent/BR112013030104A8/pt not_active Application Discontinuation
- 2012-05-25 PE PE2013002546A patent/PE20141484A1/es active IP Right Grant
- 2012-05-25 US US14/117,994 patent/US11433120B2/en active Active
- 2012-05-25 ES ES12731315T patent/ES2984717T3/es active Active
- 2012-05-25 PL PL12731315.3T patent/PL2714004T3/pl unknown
- 2012-05-25 DK DK12731315.3T patent/DK2714004T3/da active
- 2012-05-25 MX MX2013013401A patent/MX361716B/es active IP Right Grant
- 2012-05-25 CN CN201280025151.1A patent/CN103702662B/zh active Active
- 2012-05-25 SG SG2013083019A patent/SG194865A1/en unknown
- 2012-05-25 CN CN201810174910.XA patent/CN108283619B/zh active Active
- 2012-05-25 LT LTEPPCT/EP2012/059917T patent/LT2714004T/lt unknown
- 2012-05-25 KR KR1020137034307A patent/KR102066755B1/ko active Active
- 2012-05-25 JP JP2014511911A patent/JP6265888B2/ja active Active
- 2012-05-25 HR HRP20240781TT patent/HRP20240781T1/hr unknown
- 2012-05-25 RS RS20240722A patent/RS65702B1/sr unknown
- 2012-05-25 EP EP24175676.6A patent/EP4427814A3/en active Pending
- 2012-05-25 CA CA2836847A patent/CA2836847C/en active Active
- 2012-05-25 EP EP12731315.3A patent/EP2714004B1/en active Active
- 2012-05-25 PT PT127313153T patent/PT2714004T/pt unknown
- 2012-05-25 SI SI201232066T patent/SI2714004T1/sl unknown
- 2012-05-25 AU AU2012260821A patent/AU2012260821B2/en active Active
- 2012-05-25 FI FIEP12731315.3T patent/FI2714004T3/fi active
- 2012-05-25 HU HUE12731315A patent/HUE067389T2/hu unknown
- 2012-05-25 MY MYPI2013004227A patent/MY177820A/en unknown
- 2012-05-25 WO PCT/EP2012/059917 patent/WO2012160213A1/en not_active Ceased
- 2012-05-25 EA EA201391675A patent/EA036213B1/ru not_active IP Right Cessation
- 2012-05-25 TW TW101118843A patent/TWI624271B/zh active
- 2012-05-28 AR ARP120101869A patent/AR086577A1/es unknown
-
2013
- 2013-11-11 IL IL22937613A patent/IL229376B/en active IP Right Grant
- 2013-11-22 NI NI201300127A patent/NI201300127A/es unknown
- 2013-11-22 DO DO2013000275A patent/DOP2013000275A/es unknown
- 2013-11-22 CL CL2013003365A patent/CL2013003365A1/es unknown
- 2013-11-22 GT GT201300292A patent/GT201300292A/es unknown
- 2013-11-25 CU CU2013000158A patent/CU20130158A7/es unknown
- 2013-12-09 PH PH12013502550A patent/PH12013502550A1/en unknown
- 2013-12-12 CR CR20130653A patent/CR20130653A/es unknown
- 2013-12-20 ZA ZA2013/09653A patent/ZA201309653B/en unknown
- 2013-12-20 CO CO13297046A patent/CO6900117A2/es unknown
- 2013-12-24 EC ECSP13013107 patent/ECSP13013107A/es unknown
-
2016
- 2016-04-06 AU AU2016202156A patent/AU2016202156B2/en active Active
-
2017
- 2017-11-29 JP JP2017228735A patent/JP6415673B2/ja active Active
-
2021
- 2021-06-17 US US17/350,363 patent/US20210308226A1/en not_active Abandoned
-
2024
- 2024-09-18 US US18/889,001 patent/US20250121035A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201309653B (en) | Controlled release peptide formulations | |
| HUS1800036I1 (hu) | Tesztoszteron-készítmények | |
| ZA201306118B (en) | Lyophilized formulations | |
| IL236304A0 (en) | Formulations for diclofenac | |
| ZA201202474B (en) | Controlled release compositions | |
| IL227094B (en) | Immunosuppressive preparations | |
| AP3681A (en) | Modified release formulations for oprozomib | |
| EP2729164A4 (en) | FORMULATIONS STABILIZING PROTEINS | |
| ZA201308316B (en) | Sustained release paracetamol formulations | |
| GB201110278D0 (en) | Formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201111578D0 (en) | Pharmeutical formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201102795D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201104049D0 (en) | Formulations | |
| GB201105410D0 (en) | Formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |